Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: Results of an F2-study database

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3848-3853

  Solal Ceĺigny, Philippe ^a   Bellei, Monica ^d   Marcheselli, Luigi ^d   Pesce, Emanuela Anna ^d   Pileri, Stefano ^d   McLaughlin, Peter ^g   Luminari, Stefano ^e   Pro, Barbara ^g   Montoto, Silvia ⁱ   Ferreri, Andrés J M ^f   Deconinck, Eric ^b   Milpied, Noël ^c   Gordon, Leo I ^h   Federico, Massimo ^d  

^a UMR INSERM U892 CNRS 6299   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; DATA BASE; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; WATCHFUL WAITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR BURDEN; WATCHFUL WAITING;

EID: 84869109856     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4474     Document Type: Article

References (19)

1. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 22:1454-1459, 2004 (Pubitemid 41103628)
2. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984 (Pubitemid 15211022)
3. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
4. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
5. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003 (Pubitemid 36976715)
6. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117, 1997 (Pubitemid 27106296)
7. Bachy E, Brice P, Delarue R, et al: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the pre-rituximab era: Effect of response quality on survival-A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 28:822-829, 2010
8. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004 (Pubitemid 38745964)
9. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
10. Ardeshna KM, Qian W, Smith P, et al: An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): A preliminary analysis. Blood 116:21, 2010 (abstr 6)
11. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
12. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555-4562, 2009
13. Jaffe ES, Harris NL, Stein H, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
14. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29:4234-4242, 2011
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Cox D: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
17. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
18. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
19. Sinha R, Byrtek M, DeJoubner NJ, et al: Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Blood 118:21, 2011 (abstr 775)